SCHEMBL13289384

SCHEMBL13289384

Bc1cnn2c(NCCNS(=O)(=O)c3ccc(C(C)C)cc3)cc(-c3ccccc3Cl)nc12

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 5/20 0.47
▸ CDK2 P24941 5/20 0.43
▸ ALDH1A1 P00352 4/20 0.36
▸ MAPT P10636 3/20 0.36
▸ CYP1A2 P05177 2/20 0.36
▸ CYP2D6 P10635 2/20 0.36
▸ CYP2C19 P33261 2/20 0.36
▸ POLB P06746 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ MEN1 O00255 1/20 0.34
▸ PKM P14618 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ LMNA P02545 2/20 0.34
▸ TP53 P04637 2/20 0.34
▸ CCNA2 P20248 1/20 0.33
▸ CCNA1 P78396 1/20 0.33
▸ THRB P10828 1/20 0.33
▸ AHR P35869 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13289035 0.95 GSK3B (0.46) GSK3BCDK2ALDH1A1MAPTCYP1A2
SCHEMBL13289118 0.91 GSK3B (0.56) GSK3BCDK2ALDH1A1MAPTCYP1A2
SCHEMBL13289272 0.91 GSK3B (0.48) GSK3BCDK2ALDH1A1MAPTCYP1A2
SCHEMBL13289126 0.91 GSK3B (0.47) GSK3BCDK2ALDH1A1MAPTCYP1A2
SCHEMBL13289506 0.90 GSK3B (0.47) GSK3BCDK2ALDH1A1MAPTCYP1A2
SCHEMBL13121226 0.90 GSK3B (0.59) GSK3BCDK2RAB9ACCNA2CCNA1
SCHEMBL13289344 0.90 GSK3B (0.46) GSK3BCDK2ALDH1A1MAPTCYP1A2
SCHEMBL13289109 0.89 GSK3B (0.46) GSK3BCDK2ALDH1A1MAPTCYP1A2
SCHEMBL13288997 0.89 ALDH1A1 (0.49) GSK3BCDK2ALDH1A1MAPTCYP1A2
SCHEMBL13289385 0.89 GSK3B (0.47) GSK3BCDK2ALDH1A1MAPTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2194058-A1 Pyrazolopyrimidines suitable for the treatment of cancer diseases SCHERING CORPORATION (US) 2010-06-09 — — EP disclosed
Send feedback